NeuroPharma nabs $36 mln Series C
Seattle-based Impel NeuroPharma Inc, which is focused on developing treatments for central nervous disorders, has secured $36 million in Series C funding round. The investors were venBIO, 5AM Ventures and Vivo Capital.
5 December 2016•1 min read
